Study on pupillary light reflex in diseases with circadian rhythm disorders

A comparative study of melanopsin-mediated pupillary responses among diseases with concomitant circadian rhythm sleep/wake disorders

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1030230105

Enrollment

100

Registered

2023-06-02

Start date

2023-06-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pupillary light reflex is measured in DSWPD, AD spetrum patients and Healthy controls

Interventions

Measurement of post-illumination pupil response (PIPR): Red or blue LED light is presented for 1 second to subjects who have adapted to the dark.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: DSWPD patients: 1) Participants who are between 16 and 29 years old at the time of consent. 2) Participants who meet DSM-5 or ICSD-3 diagnostic criteria for DSWPD Healthy controls of DSWPD patients: 1) Participants who are between 16 and 29 years old at the time of consent. AD Spectrum Patients: 1) Participants who are between 60 and 80 years old at the time of consent. 2) Participants who meet the diagnostic criteria for AD Spectrum (Mild AD, MCI, Preclinical AD) 3) Participants who fully understand the study and give their free and voluntary written consent. Healthy controls of AD spectrum patients: 1) Participants who are between 60 and 80 years old at the time of consent. 2) Participants who fully understand the study and give their free and voluntary written consent

Exclusion criteria

Exclusion criteria: DSWPD patients: 1) Participants with neurodegenerative diseases. 2) Participants with abnormal color vision. 3) Participants with darkness phobia. 4) Other subjects deemed inappropriate by the principal investigator. Healthy controls of DSWPD: 1) Participants with psychiatric disorders. 2) Participants with neurodegenerative disorders. 3) Participants with abnormal color vision. 4) Participants with darkness phobia. 5) Other subjects deemed inappropriate by the principal investigator. AD Spectrum Patients: 1) Participants with neurodegenerative diseases other than AD Spectrum. 2) Participants with abnormal color vision. 3) Those with darkness phobia. 4) Others whom the principal investigator deems inappropriate. Healthy controls of AD spectrum: 1) Participants with psychiatric disorders. 2) Participants with neurodegenerative disorders. 3) Participants with abnormal color vision. 4) Participants with darkneess phobia. 5) Other subjects deemed inappropriate by the principal investigator.

Design outcomes

Primary

Measure	Time frame
Comparison of PIPR among DSWPD patients, AD spectrum patients, and healthy controls	—

Secondary

Measure	Time frame
Contribution of individual factors (age, gender) to group differences in PIPR	—

Contacts

Public ContactTaisuke Eto

National Center of Neurology and Psychiatry

eto@ncnp.go.jp+81-42-346-2071

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026